Advertisement
Singapore markets closed
  • Straits Times Index

    3,322.62
    +14.72 (+0.45%)
     
  • S&P 500

    5,314.68
    +7.67 (+0.14%)
     
  • Dow

    39,364.19
    -306.85 (-0.77%)
     
  • Nasdaq

    16,919.15
    +117.61 (+0.70%)
     
  • Bitcoin USD

    68,155.40
    -2,006.12 (-2.86%)
     
  • CMC Crypto 200

    1,470.40
    -32.27 (-2.15%)
     
  • FTSE 100

    8,342.36
    -27.97 (-0.33%)
     
  • Gold

    2,345.80
    -47.10 (-1.97%)
     
  • Crude Oil

    77.21
    -0.36 (-0.46%)
     
  • 10-Yr Bond

    4.4930
    +0.0590 (+1.33%)
     
  • Nikkei

    39,103.22
    +486.12 (+1.26%)
     
  • Hang Seng

    18,868.71
    -326.89 (-1.70%)
     
  • FTSE Bursa Malaysia

    1,629.18
    +7.09 (+0.44%)
     
  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     
  • PSE Index

    6,659.99
    +52.77 (+0.80%)
     

Cue Biopharma First Quarter 2024 Earnings: Beats Expectations

Cue Biopharma (NASDAQ:CUE) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$1.72m (up by US$1.53m from 1Q 2023).

  • Net loss: US$12.3m (loss narrowed by 5.8% from 1Q 2023).

  • US$0.25 loss per share (improved from US$0.29 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cue Biopharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 42%. Earnings per share (EPS) also surpassed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are down 18% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Cue Biopharma (1 can't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.